Cantor Fitzgerald Brokers Lift Earnings Estimates for SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Tuesday, November 11th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($1.89) for the year, up from their prior estimate of ($1.92). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Cantor Fitzgerald also issued estimates for ARS Pharmaceuticals’ FY2026 earnings at ($2.12) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.07). The business had revenue of $32.50 million during the quarter, compared to analysts’ expectations of $28.87 million. ARS Pharmaceuticals had a negative return on equity of 38.77% and a negative net margin of 56.06%.

Several other research firms have also commented on SPRY. Zacks Research lowered ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 22nd. Roth Capital assumed coverage on ARS Pharmaceuticals in a research note on Tuesday, November 4th. They issued a “buy” rating and a $30.00 target price on the stock. Wall Street Zen lowered shares of ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a report on Wednesday, October 8th. Finally, Raymond James Financial set a $32.00 price objective on shares of ARS Pharmaceuticals in a research note on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, ARS Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $31.80.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ:SPRY opened at $8.94 on Thursday. The firm has a 50 day moving average of $9.83 and a 200 day moving average of $13.46. The company has a quick ratio of 5.98, a current ratio of 6.66 and a debt-to-equity ratio of 1.14. The company has a market capitalization of $883.72 million, a price-to-earnings ratio of -11.04 and a beta of 0.83. ARS Pharmaceuticals has a 52 week low of $8.05 and a 52 week high of $18.90.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, CFO Kathleen D. Scott sold 12,500 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $187,500.00. Following the transaction, the chief financial officer owned 10,042 shares in the company, valued at approximately $150,630. This represents a 55.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Richard E. Lowenthal sold 50,000 shares of the firm’s stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $14.49, for a total transaction of $724,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,196,494 shares of the company’s stock, valued at approximately $17,337,198.06. This represents a 4.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 112,500 shares of company stock valued at $1,615,759. Insiders own 33.50% of the company’s stock.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alliancebernstein L.P. increased its holdings in shares of ARS Pharmaceuticals by 1.1% in the first quarter. Alliancebernstein L.P. now owns 3,922,805 shares of the company’s stock valued at $49,349,000 after purchasing an additional 42,071 shares during the period. Vanguard Group Inc. boosted its position in ARS Pharmaceuticals by 7.3% in the third quarter. Vanguard Group Inc. now owns 3,500,303 shares of the company’s stock valued at $35,178,000 after buying an additional 237,630 shares during the last quarter. Aberdeen Group plc increased its holdings in ARS Pharmaceuticals by 106.1% in the 3rd quarter. Aberdeen Group plc now owns 3,097,022 shares of the company’s stock worth $31,125,000 after buying an additional 1,594,447 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in ARS Pharmaceuticals during the 2nd quarter worth approximately $30,154,000. Finally, Cormorant Asset Management LP raised its position in ARS Pharmaceuticals by 220.0% during the 1st quarter. Cormorant Asset Management LP now owns 1,600,000 shares of the company’s stock worth $20,128,000 after buying an additional 1,100,000 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.